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Abstract
Purpose Nitroglycerin (NTG) is a vasodilating drug, which
increases tumor blood flow and consequently decreases hyp-
oxia. Therefore, changes in [18F] fluorodeoxyglucose posi-
tron emission tomography ([18F]FDG PET) uptake pattern
may occur. In this analysis, we investigated the feasibility of
[18F]FDG PET for response assessment to paclitaxel-
carboplatin-bevacizumab (PCB) treatment with and without
NTG patches. And we compared the [18F]FDG PET response
assessment to RECIST response assessment and survival.
Methods A total of 223 stage IV non-small cell lung cancer
(NSCLC) patients were included in a phase II study
(NCT01171170) randomizing between PCB treatment with
or without NTG patches. For 60 participating patients, a base-
line and a second [18F]FDGPET/computed tomography (CT)
scan, performed between day 22 and 24 after the start of treat-
ment, were available. Tumor response was defined as a 30 %
decrease in CT and PET parameters, and was compared to
RECIST response at week 6. The predictive value of these
assessments for progression free survival (PFS) and overall
survival (OS) was assessed with and without NTG.
Results A 30 % decrease in SUVpeak assessment identi-
fied more patients as responders compared to a 30 % de-
crease in CT diameter assessment (73 % vs. 18 %), how-
ever, this was not correlated to OS (SUVpeak30 p = 0.833;
CTdiameter30 p = 0.557). Changes in PET parameters be-
tween the baseline and the second scan were not signifi-
cantly different for the NTG group compared to the control
group (p value range 0.159–0.634). The CT-based (part of
the [18F]FDG PET/CT) parameters showed a significant
difference between the baseline and the second scan for
the NTG group compared to the control group (CT diam-
eter decrease of 7 ± 23 % vs. 19 ± 14 %, p = 0.016,
respectively).
Conclusions The decrease in tumoral FDG uptake in ad-
vanced NSCLC patients treated with chemotherapy with and
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without NTG did not differ between both treatment arms.
Early PET-based response assessment showed more tumor
responders than CT-based response assessment (part of the
[18F]FDG PET/CT); this was not correlated to survival.
This might be due to timing of the [18F]FDG PET shortly
after the bevacizumab infusion.
Keywords [18F]FDGPET/CT . Response assessment .
Nitroglycerin . Bevacizumab . Stage IVNSCLC
Introduction
Molecular imaging with [18F] fluorodeoxoyglucose posi-
tron emission tomography ([18F]FDG PET) has an
established role in the staging of patients with non-small
cell lung cancer (NSCLC). In addition, an increasing num-
ber of studies have shown that [18F]FDG PET is useful for
early response assessment in NSCLC patients treated with
cytotoxic chemotherapy [1–4].
Tumor hypoxia is a common phenomenon in lung cancer
and it is related to poor prognosis due to treatment resistance
[5–11]. Preclinical studies have shown that nitric oxide (NO)-
donating drugs increase blood flow and thereby decrease hyp-
oxia [12]. Nitroglycerin (NTG), a vasodilator, is such a drug.
By increasing the tumor blood flow, NTG consequently aug-
ments antitumor drug delivery and inhibits hypoxia inducible
factor (HIF-1α) [13]. In preclinical models, administration of
low doses of NTG, at least partially, reverses the hypoxia-
induced resistance to anticancer drugs [14].
Yasuda et al. [15] showed that the combination of
platinum-based chemotherapy and NTG improves overall sur-
vival (OS) in patients with stage IIIb/IV NSCLC. However,
two recent randomized studies, including the Dutch
NVALT12 study, could not confirm these results and no clin-
ical effect was observed by the addition of NTG [16, 17].
Negative correlation between perfusion computed tomog-
raphy (CT) and hypoxia PET on a population basis were also
described in literature [18], suggesting that hypoxia is nega-
tively correlated to tumor blood flow. Consequently, if treat-
ment with NTG improved tumor perfusion, this could trans-
late into a change in FDG uptake [13]. This concept was tested
in the context of the randomized NVALT12 study that sought
to investigate whether the addition of NTG to first-line
paclitaxel-carboplatin-bevacizumab (PCB) chemotherapy
would improve progression free survival (PFS).
In clinical practice, tumor response assessment is based on
changes in tumor size, according to response evaluation criteria
in solid tumors (RECIST) at week 6 [19, 20]. However, response
monitoring is complex because the tumor has to change signifi-
cantly in size and shape before a response is reliably detected by
CT [21, 22]. This leads to an underestimation of the efficacy of
cytostatic therapeutic agents that stabilize the disease, in contrast
to conventional cytotoxic drugs, which induce shrinkage of tu-
mor dimensions in the case of tumor response [19]. Metabolic
changes, measured by [18F]FDG PET, will occur earlier than
changes in size and may, therefore, be used for early treatment
response assessment. A decrease in metabolic activity of the
primary tumor after one cycle of chemotherapy treatment is pre-
dictive for better outcome [1, 18, 23, 24].
In this paper, we investigated the feasibility of [18F]FDG
PET for response assessment to PCB treatment with and with-
out NTG patches. Furthermore, we compared the [18F]FDG




In the multicentric NVALT12 trial (NCT01171170), 223 pa-
tients with metastatic non-squamous NSCLC were random-
ized between PCB with or without NTG (see [17] for patient
inclusion criteria and treatment specifications) with the prima-
ry endpoint of that trial being PFS. Response was assessed
every two cycles by the local investigator according to
RECIST 1.1 based on CT imaging [20]. In patients undergo-
ing [18F]FDG PET/CT at baseline as part of the standard
work-up (median number of days between baseline scan and
start treatment 17 days; range 73 days before treatment to 1
scan performed 1 day after the start of treatment), the protocol
pre-specified a second [18F]FDG PET/CT between day 22
and 24 (after second chemotherapy infusion and with NTG
application for patients in the experimental group; Fig. 1). To
include more patients (17) in the analysis presented here,
scans acquired with a time interval between the first chemo-
therapy and the second [18F]FDG PET/CT scan less than
35 days were accepted. This study was approved by the med-
ical ethical committee and all patients provided informed writ-
ten consent prior to any study handling.
Scan protocol
Injected [18F]FDG activity depended on individual pa-
t ient and scanner characterist ics, following the
Netherlands protocol for standardization of [18F]FDG
whole-body PET studies in mul t i -center t r ia ls
(NEDPAS) [25], which was the precursor of the
EANM guidelines, and images were reconstructed to in-
stitutional standards. Typically, a low-dose CT scan as
part of the [18F]FDG PET/CT was made, according to
institutional standards, and used for attenuation correc-
tion. Due to variations between the institutes, for quality
control purposes, a spherical volume of interest (VOI)
with a diameter of 3 cm was delineated in the right lobe
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of the liver [26]. This measurement was used as quality
index and scans with a mean standardized uptake value
(SUV) of the liver below 1.3 or above 3.0 were exclud-
ed from further analysis [27].
Early prediction of survival
The primary tumor was manually delineated by experi-
enced radiation oncologists using a treatment planning
system (Eclipse Version 11.0, Varian Medical Systems,
Inc.) and used as the region of interest (ROI). A stan-
dard delineation protocol was used, which included
fixed window/level settings of CT (lung: 1700/-300;
mediastinum: 600/40). Patients without a measurable
primary tumor on the baseline [18F]FDG PET/CT scan
were excluded from analysis.
The maximum standardized uptake value (SUVmax),
mean SUV (SUVmean), peak SUV (SUVpeak; mean up-
take in a sphere with a diameter of 1.2 cm [21]), total
lesion glycolysis (TLG; TLG was defined by SUVmean
multiplied by the tumor volume), maximal CT diameter,
and CT volume (number of voxels within the delineated
ROI multiplied by the voxel size) were calculated in our
institute on the [18F]FDG PET/CT scan (Matlab R2013a,
The Mathworks, Natrick, MA, USA) using an adapted
version of CERR (Computational Environment for
Radiotherapy Research) extended with in-house devel-
oped Radiomics image analysis software to extract imag-
ing features [28, 29]. Early metabolic response was de-
fined using relative changes in [18F]FDG PET uptake pa-
rameters of the primary tumor expressed as a percentage
change from baseline. Patients were grouped according to
a 30 % decrease in CT and PET parameters in the primary
tumor ROI of the [18F]FDG PET/CT scan [26, 30, 31].
For the PET response assessment, SUVpeak was used and
for the CT response assessment, CT diameter (CT was part
of the [18F]FDG PET/CT) was used [26, 30]. The
RECIST analysis performed during week 6 by the local
investigators was used in the analysis to separate patients
into responders and non-responders. The 30 % CT and
PET response assessments, performed after 3 weeks of
therapy, were compared against the RECIST response as-
sessment performed during week 6 by a specificity and
sensitivity analysis.
Statistics
Since normality checks suggested an abnormal distribu-
tion for the changes in CT and PET parameters from base-
line, non-parametric tests were used for the analysis of
these variables. Comparison of the mean changes in CT
and PET parameters from baseline for responders vs. non-
responders was carried out by an independent samples
Mann–Whitney U test. PFS was defined as the interval
from randomization to progressive disease or death,
whichever occurred first, and OS was defined as the in-
terval from randomization to death from any cause.
Differences in PFS and OS were investigated using Cox
regression. For calculating the hazard ratio (HR), the dif-
ferent response assessment criteria were used, as a binary
variable. To compare CT diameter and SUVmax response
with survival, in the waterfall plots a survival cut-off of
6 months was used. This is the median PFS of the com-
bined group (NTG group combined with control group).
Statistical tests were based on a two-sided significance
level, and the level of significance was set at 0.05. All
statistics were performed in SPSS v.21 (IBM Corp.
Released 2012, IBM SPSS Statistics for Windows,
Version 21.0, Armonk, NY, USA).
Results
Patients
87 out of the 223 included patients in the randomized phase II
study had two [18F]FDG PET/CTscans available with a mea-
surable primary tumor; however, 27 patients were subsequent-
ly excluded for analysis due to poor image quality (see
methods). Hence, 60 patients (characteristics in Table 1) had
-3 -2 -1 1 2 3 18 19 20 21 22 23 24 35 36 37 38 39 40 41 42 43 44 45
[18F]FDG PET/CT [18F]FDG PET/CT
Diagnostic CT Diagnostic CT
NTG patch NTG patch NTG patch
…………… ……………
Fig. 1 NVALT12 trial timeline. At day one of the 21-day cycle, the
paclitaxel-carboplatin-bevacizumab therapy is administered (grey
square). The patients in the experimental arm wear the nitroglycerin
(NTG) patch from day −3 to +2. The baseline [18F]FDG PET/CT is
performed before the start of chemotherapy and the second [18F]FDG
PET/CT is performed between day 22 and 24 (black arrow). The baseline
diagnostic CT is performed before the start of chemotherapy and repeated
after every two cycles of chemotherapy (grey arrow)
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two evaluable consecutive [18F]FDG PET/CT scans (Fig. 2)
with a median interval of 42 days. PFS and OS were similar
for patients treated with PCB and PCB +NTG (Table 1).
Image characteristics
Experimental vs. control arm
The mean decrease in SUVmax between the 31 patients
treated with PCB (46 ± 27 %) and the 29 patients treated
with PCB + NTG (42 ± 29 %) was not statistically signifi-
cantly different (p = 0.510). The other PET parameters
(SUVmean, SUVpeak and TLG) showed on average >
40 % decrease from baseline, but this was also not statis-
tically significantly different between the experimental arm
and the control arm (Fig. 3). Although for CT, part of the
[18F]FDG PET/CT, in the control arm, the CT diameter
decreased significantly more than in the experimental arm
(19 ± 14 % vs. 7 ± 23 %; p = 0.028).
Early prediction of survival
According to the 30 % PET criteria, 74 % of patients in
the control arm and 72 % of the patients in the experi-
mental arm showed response after 3 weeks (median time
interval 42 days). According to the 30 % CT criteria,
26 % of the patients in the control arm and 10 % of the
patients in the experimental arm had a response.
According to the RECIST analysis performed after 2 cy-
cles (median time interval 56 days) by the local investi-
gator, 29 % of the patients in the control arm had a re-
sponse and 17 % of the patients in the experimental arm
had a response (Table 1).
The predictive value of the 30 % CT-based and 30 % PET-
based response assessments performed after 3 weeks (on the
primary tumor) was assessed for response according to
RECIST after 2 cycles (Table 2). The 30 % PET-based re-
sponse assessment had a higher sensitivity compared to the
30 % CT-based response assessment but a lower specificity
(Table 2).
Table 1 Patient characteristics
Control Experimental
Patients analyzed 31 29
Gender Male 15 15
Female 16 14
Age (mean, range) [years] 59 (39–73) 59 (45–77)
WHO-PS 0 20 (65 %) 10 (34 %)
1 10 (32 %) 18 (62 %)
2 1 (3 %) 1 (3 %)
Smoker Current 13 (42 %) 14 (48 %)
Ex 14 (45 %) 12 (41 %)
Never 4 (13 %) 3 (11 %)
Histology Adeno 27 (86 %) 24 (83 %)
Large cell 2 (7 %) 1 (3 %)
Other 2 (7 %) 4 (14 %)
Survival (median, range) PFS [months] 7 (3–25) 4 (1–11)
OS [months] 13 (4–33) 9 (2–29)
RECIST response (week 6) Complete response 0 (0 %) 0 (0 %)
Partial response 9 (29 %) 5 (17 %)
Stable disease 20 (65 %) 17 (59 %)
Progressive disease 2 (6 %) 7 (24 %)
Baseline (mean, range) CT diameter [cm] 6.8 (2.5–12.1) 6.7 (2.4–16.4)
CT volume [cm3] 101.5 (4.4–474.5) 89.8 (3.0–468.8)
SUVmax 13.5 (3.4–28.9) 14.5 (3.6–44.6)
SUVmean 5.7 (2.5–11.8) 6.2 (2.1–22.3)
SUVpeak 11.0 (3.1–25.3) 12.1 (2.6–37.9)
TLG [SUV*cm3] 655.0 (23.4–4288.8) 638.4 (8.2–3467.2)
WHO-PS World Health Organization performance status, PFS progression-free survival, OS overall survival,
RECIST response evaluation criteria in solid tumors, SUV standardized uptake value, TLG total lesion glycolysis
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The 30 % CT-based and 30 % PET-based response assess-
ments were for neither of the arms predictive for PFS nor OS
(Table 3).
The changes in CT diameter and SUVmax between base-
line and early response assessment were depicted in a water-
fall plot showing that PET definedmore patients as responders
than CT (Fig. 4 and Table 2). However, this decline was not
predictive for longer PFS (than 6 months).
Discussion
The hypothesis of the NVALT12 trial was that the addition
of NTG, by increasing tumor blood flow and oxygenation
status, would improve outcome. While the clinical study of
the NVALT12 already showed that NTG did not improve
outcome, in the current study, we investigated if we could
predict outcome based on early response assessment using
[18F]FDG PET imaging [17]. This image analysis study of
the NVALT12 trial could not show a predictive value of
[18F]FDG PET imaging for the evaluation of the addition of
NTG to bevacizumab-containing chemotherapy when com-
pared to control patients. In a previous study, the administration
of NO donating drugs decreased hypoxia-induced resistance
to anticancer drugs in cancer cell lines [14]. In the
NVALT12 trial, this could not be confirmed based on
[18F]FDG PET analysis. This could be due to a lower
NTG dose than that used in the Yasuda study [15], or to
an interference with bevacizumab. From recent studies, it
is known that FDG is only a moderate surrogate for hyp-
oxia [32]. The study of Zegers et al. [33] showed that 42 ±
21 % of the primary tumor volume has a high FDG uptake
(SUV > 50 % of SUVmax) of which 10 ± 12 % is hypoxic
(high [18F]HX4 uptake TBR > 1.4), and that 3 % of the
primary tumor volume outside the high FDG uptake vol-
ume is hypoxic as depicted by [18F]HX4 PET. In our
study, we, therefore, only measure the effects of NTG on
tumor metabolism and survival but not on hypoxia direct-
ly. Surprisingly, in nearly all patients, irrespective of treat-
ment arm, a major decrease in FDG uptake was observed
in the [18F]FDG PET scan performed after 3 weeks.
Importantly, this [18F]FDG PET scan was acquired within
3 days after administration of the second cycle of chemo-
therapy. A study by van der Veldt et al. [34] showed that
bevacizumab reduces tumor perfusion and [11C] docetaxel
uptake in NSCLC, which was accompanied by rapid re-
duction in circulating levels of VEGF. This decrease in tumor
blood flow after bevacizumab administration may explain the
Fig. 2 CONSORT diagram.
SUV: standardized uptake value
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lower uptake of FDG in the tumor. Consequently, our
results do not exclude the possibility that NTG decreases
hypoxia.
A number of studies have demonstrated that changes in
SUV parameters as early as the third week after the start
of treatment are predictive for response to chemotherapy
and PFS [1, 23, 24, 35]. A variety of approaches have
been developed to measure the response, starting with
the World Health Organization (WHO) criteria and con-
tinuing to RECIST and RECIST 1.1 [20, 26, 36]. These
criteria refer to an anatomical decrease in tumor diameter.
However, this response must be viewed with some cau-
tion when one is trying to predict outcomes in therapies
that may be more cytostatic than cytotoxic. With such
therapies, lack of progression may be associated with a
good improvement in outcome, even in the absence of
major shrinkage of tumors [37]. Newer metrics such as
PET may be more informative [38]. PET/CT-based re-
sponse evaluation has proven to be valuable in chemo-
therapy [39]. Currently, two sets of treatment response
criteria for PET are available: EORTC and PET response
criteria in solid tumors (PERCIST) [30]. PERCIST
operates with a fixed ROI of 1 cm3 in the most
[18F]FDG-avid part of the single most metabolically ac-
tive tumor in the patient at each PET/CT scan. In the
current study, a specific ROI, defining the primary tumor,
was used for response evaluation. A consideration for an-
atomic and functional imaging is that many of the changes
in response are at the border zones between response
groups.
These border zones are quite artificial, as changes in
tumor size are on a continuous scale (Fig. 3). The com-
parison of 30 % CT-based and 30 % PET-based re-
sponse assessment performed after 3 weeks (median
time interval between scans 42 days) with the RECIST
analysis performed in week 6 (median time interval be-
tween scans 56 days) showed that the RECIST analysis
defined more patients as responders than the 30 % CT-
based analysis performed after 3 weeks. This can be
caused by the difference in timing but also due to the
fact that for the 30 % CT-based analysis, only one le-
sion was measured while in RECIST, multiple lesions
were measured. The 30 % PET-based response assess-
ment performed after 3 weeks showed more responders
than the RECIST analysis, which is probably caused by
Fig. 3 Mean values and standard deviations for the CT- and PET-derived
image parameters for the experimental arm and the control arm. p values
of the independent samples Mann–Whitney U test of the mean change
from baseline of the control arm vs. the mean change from baseline of the
experimental arm (*significantly different for the experimental arm com-
pared to the control arm with a significance level of 5 %). SUV: standard-
ized uptake value; TLG: total lesion glycolysis
Table 2 Comparison of 30 %
CT-based and 30 % PET-based
response assessment performed
after 3 weeks with the RECIST
response assessment of week 6
RECIST RECIST Total
Responder Non-responder
CT diameter decrease >30 % 9 (15 %) 2 (3 %) 11 (18 %)
CT diameter decrease <30 % 17 (28 %) 32 (54 %) 49 (82 %)
26 (43 %) 34 (57 %) 60 (100 %)
Sensitivity = 35 % Specificity = 94 %
SUVpeak decrease >30 % 23 (38 %) 21 (35 %) 44 (73 %)
SUVpeak decrease <30 % 3 (5 %) 13 (22 %) 16 (27 %)
26 (43 %) 34 (57 %) 60 (100 %)
Sensitivity = 88 % Specificity = 38 %
SUV standardized uptake value, RECIST response evaluation criteria in solid tumors
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decreased perfusion due to the bevacizumab treatment,
which led to a decrease in FDG uptake for both treat-
ment arms. The response assessment for PET was not
influenced by NTG. A previous study of our group showed
that after 3 weeks of treatment, five of nine patients were
classified as responder by CTwhile six of nine were classified
as responders by [18F]FDG PET [40]. In the same study,
patients with a metabolic response (decrease in SUV >
20 %) at week 3 had a longer PFS than those without
(9.7 months vs. 2.8 months), while patients with a response
on CT at week 3 did not have a significantly longer PFS than
those without. These two findings combined showed that PET
may be able to show treatment response earlier than CT. In the
former study, [18F]FDG PET scans were performed before
bevacizumab infusion, while in our study the [18F]FDG
PET scan was performed shortly after bevacizumab infusion.
This might have impacted the uptake of FDG. A study of
Hoekstra et al. [41] also shows that [18F]FDG PET has addi-
tional value over conventional radiologic techniques for mon-
itoring response in locally advanced NSCLC patients.
The scans used for this study were made within the
scope of the Dutch multicenter NVALT12 phase II trial
and 60/223 patients underwent 2 [18F]FDG PET scans
with the second scan after cycle 2, but before day 35. For
quality control purposes, only scans with a mean SUV in
the liver between 1.3 and 3 were used, reducing the num-
ber of assessed patients in this analysis to only 60 of the
223 original patients. For the analysis, these 60 patients
were also divided between the control and the experimen-
tal arm, which means the study cohort was limited in size,
hampering in-depth subgroup analyses.
Conclusion
The addition of NTG did not lead to enhanced reduction in
FDG uptake compared to the control arm. Although PET-
based response assessment identified more responders than
CT-based response assessment, this did not correlate to
progression-free survival or overall survival. This might be

















































Fig. 4 Change in CT diameter (upper) and SUVmax (lower) from base-
line in individual patients. Patients of the experimental arm are plotted in
red, patients of the control arm in blue. The pattern-filled bars represent
patients with a progression free survival longer than 6 months. The black
line represents the used response threshold of 30 %. SUV: standardized
uptake value; PFS: progression-free survival
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Table 3 The hazard ratios (HR) for 30 % PET- and CT-based response assessment with 95 % confidence interval and corresponding p values for OS
and PFS are shown per parameter
SUV parameter PFS OS
HR (95 % CI) p value HR (95 % CI) p value
30 % response assessment SUVmax 1.048 (0.591–1.858) 0.874 1.025 (0.572–1.837) 0.934
SUVmean 0.941 (0.527–1.680) 0.838 0.901 (0.501–1.619) 0.726
SUVpeak 0.929 (0.514–1.679) 0.807 0.938 (0.515–1.706) 0.833
TLG 0.706 (0.355–1.406) 0.323 1.511 (0.722–3.160) 0.273
CTvolume 1.073 (0.617–1.866) 0.802 1.338 (0.740–2.419) 0.335
CTdiameter 0.718 (0.370–1.390) 0.325 0.805 (0.390–1.662) 0.557
SUV standardized uptake value, TLG total lesion glycolysis, PFS progression free survival,OS overall survival,HR hazard ratio, CI confidence interval
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